🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Dishman Carbogen Amcis Limited DCAL NSEPHARMA

Healthcare · Biotechnology · India
https://imdcal.com

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.

READ MORE ›
₹194.70
-26.74% 1Y

Market & Price

Market Cap
₹3,052.57 Cr
Current Price
₹194.70
High / Low (52W)
₹314.40 / ₹129.97
Beta
0.64

Valuation

Stock P/E
31.35
Industry PE
37.60
Forward P/E
15.58
PEG Ratio
-
Book Value
₹426.90
Price to Book
0.46
P/S
1.04
EV/EBITDA
9.04
Dividend Yield
-

Profitability & Returns

ROCE
2.91%
ROE
1.56%
ROA
1.29%
Profit Margin
3.32%
Op Margin
8.71%
EPS (Latest Qtr)
₹1.39
EPS (TTM)
₹6.21

Balance Sheet & Liquidity

Debt/Equity
0.46
Quick Ratio
0.72
Current Ratio
1.23
Debt
₹3,076.06 Cr
Total Assets
₹11,923.31 Cr
Current Assets
₹2,842.10 Cr
Working Capital
₹525.05 Cr

Ownership

Promoter Holding
69.30%
Chg in Prom Hold
-
FII / Inst Holding
2.50%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹5,113.84 Cr
Total Revenue (TTM)
₹2,931.90 Cr
EBITDA
₹565.63 Cr
Free Cash Flow
₹30.94 Cr
Operating Cash Flow
₹491.45 Cr
Shares Outstanding
₹15.68 Cr
Gross Margin
86.06%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
8.19%
Profit 5Y
142.34%
Revenue (YoY)
18.90%
Earnings (YoY)
-49.50%

PROS

  • Profit CAGR of 142.3% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 38.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 DCAL Dishman Carbogen Amcis Limited NSEPHARMA 194.70 31.35 ₹3,052.57 Cr - 2.91% 1.56% 8.19% 142.34%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue -682.34 Cr716.34 Cr708.05 Cr719.80 Cr851.40 Cr
Cost of Revenue -98.83 Cr145.91 Cr98.09 Cr141.48 Cr134.91 Cr
Gross Profit -583.51 Cr570.43 Cr609.96 Cr578.32 Cr716.49 Cr
Operating Expenses -515.35 Cr496.83 Cr550.63 Cr549.63 Cr642.33 Cr
Operating Income -68.16 Cr73.60 Cr59.33 Cr28.69 Cr74.16 Cr
EBITDA -147.80 Cr148.91 Cr162.78 Cr119.77 Cr178.22 Cr
Interest Expense -48.78 Cr42.12 Cr42.76 Cr45.79 Cr43.30 Cr
Pretax Income -27.05 Cr27.70 Cr38.67 Cr-10.44 Cr46.13 Cr
Tax Provision -22.42 Cr-15.39 Cr15.26 Cr2.53 Cr24.39 Cr
Net Income -4.63 Cr43.09 Cr23.41 Cr-12.97 Cr21.74 Cr
Diluted EPS -0.302.751.49-0.831.39

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -2,315.05 Cr2,543.62 Cr2,711.50 Cr2,931.90 Cr
Cost of Revenue -534.21 Cr611.61 Cr501.65 Cr408.79 Cr
Gross Profit -1,780.84 Cr1,932.01 Cr2,209.85 Cr2,523.11 Cr
Operating Expenses -1,675.35 Cr1,973.33 Cr2,034.65 Cr2,296.17 Cr
Operating Income -105.49 Cr-41.32 Cr175.20 Cr226.94 Cr
EBITDA -300.52 Cr302.01 Cr472.51 Cr617.77 Cr
Interest Expense -74.39 Cr113.41 Cr159.46 Cr174.18 Cr
Pretax Income --54.59 Cr-122.26 Cr19.31 Cr104.90 Cr
Tax Provision --24.79 Cr31.19 Cr16.07 Cr7.45 Cr
Net Income --29.80 Cr-153.45 Cr3.24 Cr97.45 Cr
Diluted EPS --1.90-9.790.216.22

Compounded Sales Growth

5 Years:8.19%
1 Year:18.90%

Compounded Profit Growth

5 Years:142.34%
1 Year:-49.50%

Stock Price Performance

1 Year:-26.74%
6 Months:-15.88%
3 Months:+7.40%
1 Month:+7.39%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -9,453.50 Cr9,581.41 Cr9,999.15 Cr11,923.31 Cr
Current Assets -1,918.36 Cr1,928.19 Cr2,200.42 Cr2,842.10 Cr
Cash & Equivalents -131.79 Cr264.09 Cr285.67 Cr787.76 Cr
Inventory -803.80 Cr882.89 Cr900.24 Cr1,019.12 Cr
Receivables -589.91 Cr484.47 Cr665.14 Cr672.91 Cr
Total Liabilities -3,643.83 Cr3,953.91 Cr4,167.63 Cr5,246.41 Cr
Current Liabilities -1,798.39 Cr2,554.72 Cr1,924.79 Cr2,317.05 Cr
Long Term Debt -1,043.22 Cr243.23 Cr1,147.02 Cr1,534.86 Cr
Total Debt -2,208.85 Cr2,312.60 Cr2,388.95 Cr3,076.06 Cr
Total Equity -5,809.67 Cr5,627.50 Cr5,831.52 Cr6,676.90 Cr
Shares Outstanding -15.68 Cr15.68 Cr15.68 Cr15.68 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -265.95 Cr379.43 Cr371.28 Cr491.45 Cr
Investing Cash Flow --494.08 Cr-229.52 Cr-192.21 Cr-245.34 Cr
Financing Cash Flow -249.67 Cr-22.15 Cr-102.09 Cr200.58 Cr
Capital Expenditure --619.68 Cr-303.25 Cr-216.76 Cr-266.61 Cr
Free Cash Flow --353.73 Cr76.18 Cr154.52 Cr224.84 Cr
Net Change in Cash -21.54 Cr127.76 Cr76.98 Cr446.69 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -76.9%76.0%81.5%86.1%
Operating Margin % -4.6%-1.6%6.5%7.7%
Net Margin % --1.3%-6.0%0.1%3.3%
ROE % --0.5%-2.7%0.1%1.5%
ROCE % -1.4%-0.6%2.2%2.4%

Shareholding Pattern

Insiders
69.30%
Institutions
2.50%
Public Float
8.14%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DCAL

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space